30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q14 Revenue: Baxano Surgical

$4.4MM, +42% (U.S. $4.3MM, +65%; ex-U.S. $0.1MM, -80%)

Domestic product sales are pro forma.

  • iO-Flex $2.4MM (U.S. $2.3MM, -21%)
  • AxiaLIF $1.2MM (U.S. $1.1MM, -42%)
  • VEO $0.57MM (U.S. $0.56MM, -5%)
  • iO-Tome $0.13MM


  • Surgeon users consistent with 4Q13, but case volume/cases per surgeon materially down due to weather, elective surgeries (volumes bounced back in early 2Q)
  • Notes traction in marketing AxiaLIF to spine surgeons with a larger mix of Medicare patients
  • >13,000 AxiaLIF cases performed to date
  • Moving to hybrid distribution model of direct (in geographies with strong, tendered reps) and established distributors with existing surgeon relationships (consolidation in spine is yielding available distributors)
  • In early 2Q, received 510(k) clearance of Avance MIS Pedicle Screw; will launch late 2Q
  • Planning limited release of TLIF system in 4Q14/1Q15